rofecoxib has been researched along with Ulcer in 3 studies
Ulcer: A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lugardon, S | 1 |
| Lapeyre-Mestre, M | 1 |
| Montastruc, JL | 1 |
| Calvo, N | 1 |
| Iversen, E | 1 |
| Munck, LK | 1 |
| Murphy, JO | 1 |
| Ravi, N | 1 |
| Byrne, PJ | 1 |
| McDonald, GS | 1 |
| Reynolds, JV | 1 |
3 other studies available for rofecoxib and Ulcer
| Article | Year |
|---|---|
Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Celecoxib; Cyclooxygenase 2; Cyclo | 2004 |
[Intestinal side effects of COX-2 inhibitors].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colonic Diseases; Colonic Pouches; | 2006 |
Neither antioxidants nor COX-2 inhibition protect against esophageal inflammation in an experimental model of severe reflux.
Topics: Animals; Antioxidants; Ascorbic Acid; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; | 2007 |